MS-Stat Clinical Trial

15 May 2017

We are pleased to announce that the Anne Rowling Regenerative Neurology Clinic will be one of the main recruiting sites for the forthcoming MS-Stat clinical trial.

MS-Stat is a phase 3 trial involving more than 1,000 people with multiple sclerosis (MS) to investigate whether simvastatin could become a treatment for progressive MS.  

The trial will test simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. There are currently no licensed treatments that can slow or stop disability progression in people with this type of MS. A phase 2 trial of 140 peope with secondary progressive MS into simvastatin at UCL Institute of Neurology led by Dr Jeremey Chataway, found that those taking high doses of the drug had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of the study.

It is hoped that the phase 3 trial will establish definitively whether simvastatin is able to show the rate of disability progression over a three year period, with the trial expected to start at the Anne Rowling Clinic later this year.

If you have a diagnosis of secondary progressive MS, attend the Anne Rowling Clinic and are interested in registering your interest to participate in the study (exclusion criteria will apply to this study), then please register your name on our new Rowling-CARE platform. Alternatively, you can register your interest with the MS Society.

Funding Acknowledgements

This study is supported by the Anne Rowling Regenerative Neurology Clinic, and funded by MS Society, UCL and the National Institute for Health Research.


Back to news